x
Search
Development Plan
> Development Plan
Overall schedule
Indication
2025
Q1
Q2
Q3
Q4
2026
Q1
Q2
Q3
Q4
2027
Q1
Q2
Q3
Q4
2028
Q1
Q2
Q3
Q4
2029
Q1
Q2
Q3
Q4
aGvHD
P1
P2
Lymphodepletion for CAR-T
IIT/ P1
P2
Cutaneous T cell lymphoma
P2
P2 Randomization
Induction therapy in
renal transplant
P1
P2
Oncology
CTCL

P1 CTCL trial showed robust potency and good safety, with four patients achieving clinical cure

P2 pivotal trial received FDA clearance to initiate

CAR-T

A non-chemo alternative; potentially a best-in-class lymphodepletion agent to broaden the addressable patient population, including the elderly

Development collaboration with Moffitt Cancer Center

Solid tumor

FDA approved IND for VG712 in combination with anti-checkpoint inhibitors to treat melanoma

In discussions with potential collaboration partners

PTCL

Received FDA clearance to initiate Phase I clinical trial

Joint development by cooperating institutions

Immunotolerance

Organ transplantation

Implications for clinical application: potentially better efficacy vs. rATG to prevent acute rejection


GvHD

Data from the GvHD model of humanized mice showed that VG712 can significantly prolong survival in mice with GvHD

Received FDA clearance to initiate Phase I clinical trial in aGvHD

Potential to induce LT tolerance and treat GvHD

HIV

VG712: “Kill and clear”

T cell lysis releases latent HIV-1 Virus

Combination therapy with neutralizing antibody to clear virus

Autoimmune Diseases

Long term use of immunosuppressive drugs eventually compromises activities of the immune system

VG 712 has the potential to “reset” immune system by depletion of defective T cells and inducing proliferation of healthy new T cells

Pre-clinical work underway